Chan Y. Cheah

Oral presented at ASH 2022 describing the potential for treating patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) with either a BCL2 inhibitor alone or a BCL2 inhibitor in combination with a BTK inhibitor.

Chatta med BeiGene

Stäng